Biogen Idec to discontinue development of ALS drug

Weston, Mass.-based Biogen Idec has decided to discontinue development of dexpramipexole in amyotrophic lateral sclerosis (ALS), after top-line results of EMPOWER, its phase III trial, did not meet it…

---

Tranzyme, BMS Complete Drug Pact

Compounds transferred to BMS for further development…

---

Biogen Idec, Inc. (Massachusetts) to Offset Tax for Gay Staff

Amit Rakhit earns the same salary as other vice presidents leading drug development teams at the Weston-based biotech company Biogen Idec, but, because he is gay, he ends up bringing home about $3,000…

---

Takeda, Amylin terminate anti-obesity compound development deal

Takeda Pharmaceutical Company and Amylin Pharmaceuticals have mutually terminated their worldwide agreement signed in October 2009 to co-develop and commercialize anti-obesity compounds.

---